Luxor Capital Group LP Purchases Shares of 247,240 Becton, Dickinson and Company $BDX

Luxor Capital Group LP purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 247,240 shares of the medical instruments supplier’s stock, valued at approximately $38,874,000. Becton, Dickinson and Company makes up 2.7% of Luxor Capital Group LP’s holdings, making the stock its 10th largest holding.

Other large investors have also recently modified their holdings of the company. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company during the third quarter valued at approximately $25,000. Steph & Co. grew its holdings in Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the last quarter. SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter worth $26,000. Meeder Asset Management Inc. increased its position in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. Finally, Main Street Group LTD purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at $29,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $156.26 on Friday. The firm has a market capitalization of $43.06 billion, a PE ratio of 39.56, a price-to-earnings-growth ratio of 11.06 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company’s fifty day moving average price is $149.95 and its 200-day moving average price is $164.97.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same quarter last year, the business posted $3.35 EPS. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Insider Activity

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 5,188 shares of company stock valued at $765,120. Company insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research note on Monday, July 6th. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Finally, Stifel Nicolaus cut their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $180.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.